Reaction
Biliary Obstruction reporting signals
As of the last recalculation, Biliary Obstruction appears in 1,235 FAERS reports alongside 37 co-occurring drug terms. The strongest observed disproportionality signal is PANCRELIPASE (PRR 37.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pancrelipase | 81 | 37.8 | 37.9 |
| Durvalumab | 37 | 31.6 | 31.6 |
| Lanreotide Acetate | 13 | 28.2 | 28.3 |
| Octreotide Acetate | 48 | 27.4 | 27.5 |
| Irinotecan Hydrochloride | 17 | 22.6 | 22.6 |
| Trifluridine And Tipiracil | 13 | 20.6 | 20.7 |
| Gemcitabine | 44 | 19.5 | 19.5 |
| Polatuzumab Vedotin | 10 | 17.4 | 17.4 |
| Gemcitabine Hydrochloride | 51 | 16.9 | 16.9 |
| Ursosiol | 18 | 15.8 | 15.8 |
| Mycophenilic Acid | 19 | 15.7 | 15.7 |
| Teduglutide | 12 | 15.1 | 15.2 |
| Lenvatinib | 28 | 14.7 | 14.7 |
| Ursodiol | 18 | 14.1 | 14.1 |
| Regorafenib | 9 | 13.2 | 13.2 |
| Atezolizumab | 27 | 12.0 | 12.0 |
| Terbinafine Hydrochloride | 6 | 11.4 | 11.4 |
| Everolimus Tablets | 11 | 11.1 | 11.2 |
| Encorafenib | 6 | 10.3 | 10.3 |
| Naproxen Sodium Tablet, Coated | 8 | 10.0 | 10.0 |
| Naproxen Sodium, Coated Tablets | 8 | 10.0 | 10.0 |
| Naproxen Sodium 220Mg | 8 | 10.0 | 10.0 |
| Bendamustine Hcl | 9 | 9.8 | 9.9 |
| Temozolomide | 11 | 8.9 | 8.9 |
| Risankizumab-Rzaa | 37 | 7.8 | 7.8 |
| Vincristine Sulfate | 13 | 7.5 | 7.5 |
| Nivolumab | 42 | 7.5 | 7.5 |
| Cisplatin | 33 | 7.3 | 7.3 |
| Pembrolizumab | 43 | 7.1 | 7.1 |
| Fam-Trastuzumab Deruxtecan-Nxki | 4 | 6.7 | 6.7 |
| Brentuximab Vedotin | 4 | 6.6 | 6.6 |
| Cabozantinib | 17 | 6.0 | 6.0 |
| Alpelisib | 3 | 5.8 | 5.8 |
| Tirzepatide | 43 | 4.6 | 4.6 |
| Axitinib | 5 | 4.3 | 4.3 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 3 | 4.1 | 4.1 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 3 | 3.8 | 3.8 |